Westhampton Capital LLC Grows Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Westhampton Capital LLC grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 0.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 27,417 shares of the biopharmaceutical company’s stock after acquiring an additional 200 shares during the period. Westhampton Capital LLC’s holdings in Bristol-Myers Squibb were worth $1,551,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Busey Bank raised its position in Bristol-Myers Squibb by 1.7% during the 4th quarter. Busey Bank now owns 214,069 shares of the biopharmaceutical company’s stock valued at $12,108,000 after purchasing an additional 3,487 shares in the last quarter. Abel Hall LLC increased its stake in shares of Bristol-Myers Squibb by 2.0% during the fourth quarter. Abel Hall LLC now owns 17,743 shares of the biopharmaceutical company’s stock valued at $1,004,000 after buying an additional 341 shares during the period. Synergy Asset Management LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $246,000. Baron Wealth Management LLC lifted its stake in Bristol-Myers Squibb by 6.6% in the fourth quarter. Baron Wealth Management LLC now owns 4,329 shares of the biopharmaceutical company’s stock worth $245,000 after acquiring an additional 268 shares during the period. Finally, Gries Financial LLC grew its holdings in Bristol-Myers Squibb by 194.3% during the 4th quarter. Gries Financial LLC now owns 51,247 shares of the biopharmaceutical company’s stock worth $2,899,000 after acquiring an additional 33,832 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $59.11 on Thursday. The stock has a 50-day moving average of $57.56 and a two-hundred day moving average of $52.97. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The stock has a market cap of $119.88 billion, a P/E ratio of -16.46, a P/E/G ratio of 2.02 and a beta of 0.45. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same quarter in the prior year, the firm earned $2.00 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 8.4% on a year-over-year basis. As a group, research analysts predict that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a $0.62 dividend. The ex-dividend date is Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.20%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio is presently -69.08%.

Analysts Set New Price Targets

BMY has been the subject of several research reports. TD Cowen upped their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Jefferies Financial Group upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and upped their target price for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Truist Financial lifted their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Barclays upped their price objective on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a research note on Monday, October 7th. Finally, Wolfe Research assumed coverage on Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $56.60.

Insider Buying and Selling

In related news, EVP Samit Hirawat purchased 1,830 shares of the business’s stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $54.67 per share, with a total value of $100,046.10. Following the transaction, the executive vice president now owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares in the company, valued at $654,091.20. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.